Investor Presentation
Investor Presentation

Perth, Mar 6, 2015 AEST (ABN Newswire) - PhytoTech Medical Limited (googlechartASX:PYL) is focused on the research and development of products for administering MGC, and new treatments utilising MGC therapeutic components for various medical conditions.

The Company is backed by a strong intellectual property portfolio, working in conjunction with leading Israeli research centers, utilising decades of medical cannabis research leadership and science/evidence-based patient trials.

The Company has an exclusive research and licensing agreement with Yissum, the prestigious Research and Development and technology transfer Company of Hebrew University in Jerusalem.

In parallel, PhytoTech Medical is developing strategic alliances with other medical cannabis companies around the world to acquire sophisticated genetic plant strains and already established growing operations.

To view the presentation, please visit:
http://media.abnnewswire.net/media/en/docs/ASX-PYL-711975.pdf


About MMJ Group Holdings Ltd

Phytotech Medical ASX:PYL

MMJ Group Holdings Ltd (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: https://www.mmjphytotech.com.au/investors/

https://plus.google.com/112611716213432048650/posts https://www.youtube.com/channel/UCkDxKKC_fe2TdZfeVSpPVhw abnnewswire.com 


Contact

Investor and Media Enquiries:
Jason Conroy
Chief Executive Officer
T: +61-2-8098-0819
E: info@mmjgh.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 5) (Last 30 Days: 28) (Since Published: 5521)